 |
|
OCP Workshops and Seminars
American College of Clinical Pharmacology,
September 11, 2005, Emerging Pharmacogenomic Tools & Their Utility in
Benefit/Risk Assessment During Drug Development & in Clinical Trials
- Emerging Pharmacogenomic Tools & Their Utility in Benefit/Risk Assessment During Drug Development & in Clinical Trials - Introduction, [PDF]
Shiew-Mei Huang, Ph.D., CDER
- Clinical Pharmacogenetics- Why We Don’t Have It. How We Can Get It, [PDF] David Flockhart, M.D., Ph.D., Indiana University
- Whole Genome Association Study and Risk Assessment, [PDF] David Cox, M.D., Perlegen
- Pharmacogenetics: Lessons from Anti-Epileptic Drugs,
[PDF] David Goldstein, Ph.D., Duke
- How Pharmacogenomics Will Revolutionize Oncology Clinical Trials, [PDF]
Richard Pazdur, M.D., CDER
- Case Studies, [PDF] Susan T. Hall, Ph.D.,
Moderator, GlaxoSmithKline
Workshop on Drug
Metabolizing Enzymes and Pharmacogenomic Testing, Sept. 13-14, 2004
- Regulatory Issues in Genotyping:
Metabolizing Enzymes CDER Perspective, Shiew-Mei Huang, Ph.D., CDER
- CYP2D6, David A. Flockhart M.D.,
Ph.D., Indiana University School of Medicine
- Special Considerations for Individual Metabolic
Biomarkers: CYP2C9, Patrice M. Milos, Ph.D., Pfizer
- CYP2C19, Tommy Andersson, Ph.D.,
AstraZeneca
- UGT1A1: Focus on
Irinotecan, Mark J. Ratain, MD, University of Chicago
- Special Considerations for Individual Biomarkers: P-gp,
Deanna L. Kroetz, Ph.D., University of California San Francisco
- Haplotype Mapping of ADME Genes,
David Goldstein, Ph.D.,
University College London
 PDF requires the free Adobe
Acrobat Reader
 Back
to Top  Back to OCP
|
|
|
.gif){kind=spacer}